Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis

Tuberculosis and Respiratory Diseases

article

Seong Woo Go¹  Boo Kyeong Kim¹  Sung Hak Lee²  Tae-Jung Kim²  Joo Yeon Huh¹  Jong Min Lee¹  Jick Hwan Hah¹  Dong Whi Kim¹  Min Jung Cho¹  Tae Wan Kim¹  Ji Young Kang¹ 

[1] Department of Internal Medicine, The Catholic University of Korea College of Medicine;Department of Pathology, The Catholic University of Korea College of Medicine

关键词: Leukemia;    Myelogenous;    Chronic;    BCR-ABL Positive;    Imatinib;    Lung Diseases;    Interstitial;   

DOI  :  10.4046/trd.2013.75.6.256

学科分类：医学（综合）

来源: The Korean Academy of Tuberculosis and Respiratory Diseases

【 摘 要 】

Imatinib mesylate is a targeted therapy that acts by inhibiting tyrosine kinase of the bcr-abl fusion oncoprotein, which is specific to chronic myeloid leukemia (CML), and the c-transmembrane receptor, which is specific to gastrointestinal stromal tumors. Interstitial pneumonitis is a rare adverse event of imatinib therapy. It is clinically difficult to distinguish from infectious pneumonia, which can frequently occur due to the underlying disease. The standard treatment for imatinib-induced pneumonitis is to discontinue the medication and optionally administer corticosteroids. However, there are a few cases of successful retrial with imatinib. We describe a case of successful rechallenge of imatinib in a patient with imatinib-induced interstitial pneumonitis and CML without a recurrence of the underlying disease after 3 months of follow-up.

【 授权许可】

CC BY-NC